Important safety information including dosage, side effects, and precautions of Oseltamivir.
Dosage & Administration
・(For flu prevention) Adults and children weighing 37.5 kg or more should take 1 tablet once daily.
・If you miss a dose, take it as soon as possible. If it’s almost time for your next dose, skip the missed one and continue your regular schedule.
・Do not take two doses at the same time.
Side Effects
The most commonly reported side effects include rash, diarrhea, abdominal pain, nausea, vomiting, dizziness, headache, insomnia and low body temperature. If any of these symptoms occur, consult with your doctor or pharmacist.
Serious Side Effects
If you develop any of the serious side effects listed below, discontinue use and visit a medical facility immediately:
・Hives, facial/pharyngeal edema, respiratory distress [shock, anaphylaxis]
・General malaise, loss of appetite, yellow discoloration of the skin and the white of eyes [fulminant hepatitis, liver dysfunction, jaundice]
・Fever, redness and swelling of skin/mucosa with rash or blisters, conjunctival hyperemia [mucocutaneous ocular syndrome, toxic epidermal necrolysis]
・Decreased urine output, edema, headache [acute renal disorder]
・Consciousness disorder, delirium, sudden running/wandering [psychiatric/neurological symptoms, abnormal behavior]
Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.
Precautions
・Do not take this medication if you have kidney dysfunction, are pregnant or breastfeeding, and do not give to children under 1 year old.
・Keep out of the reach of children. Store away from direct sunlight, heat and moisture.
Approval status in Japan
・「アレルギー性鼻炎、蕁麻疹、皮膚疾患（湿疹・皮膚炎、皮膚そう痒症）に伴うそう痒」を効能として承認されています。
※本診療科目で処方する医薬品は、医薬品副作用被害救済制度の対象外となります。
Availability of approved medicines that have the same active ingredients in Japan
・同じ有効成分を有し「アレルギー性鼻炎、蕁麻疹、皮膚疾患（湿疹・皮膚炎、皮膚そう痒症）に伴うそう痒」を効能として承認されている内服薬はありません。
Means of acquisition
・提携クリニックの医師が、国内医薬品販売代理店経由で購入しています。
Information on safety and approval in other countries
・諸外国で重篤な安全性情報の報告はありません。